Ad
related to: liver lipogenesis syndrome
Search results
Results From The WOW.Com Content Network
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), [a] is a type of chronic liver disease. This condition is diagnosed when there is excessive fat build-up in the liver ( hepatic steatosis ), and at least one metabolic risk factor.
Lipogenesis plays a role in energy intake and expenditure, lipid deposition, insulin sensitivity, cancer, cardiovascular disease, the immune system, and neurogenesis. Potential therapeutic applications for inhibitors include non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease. [1] [2]
27141 12684 Ensembl ENSG00000136305 ENSG00000285199 ENSMUSG00000022219 UniProt Q9UHD4 O70303 RefSeq (mRNA) NM_014430 NM_001318807 NM_009894 NM_026804 RefSeq (protein) NP_001305736 NP_055245 NP_034024 Location (UCSC) Chr 14: 24.31 – 24.31 Mb Chr 14: 55.99 – 56 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Cell death-inducing DFFA-like effector b, also known as CIDEB, is a human ...
Average patient lifespan is approximately 30 years before death, with liver failure being the usual cause of death. [8] In contrast to the high levels seen in non-alcoholic fatty liver disease (NAFLD) associated with obesity, leptin levels are very low in lipodystrophy.
17β-HSD13 is significantly up-regulated in the liver of patients with non-alcoholic fatty liver disease (NAFLD) and enhances lipogenesis. [7] Inhibitors
Fatty liver disease (FLD), also known as hepatic steatosis and steatotic liver disease (SLD), is a condition where excess fat builds up in the liver. [1] Often there are no or few symptoms. [ 1 ] [ 2 ] Occasionally there may be tiredness or pain in the upper right side of the abdomen . [ 1 ]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
An excess of free fatty acids in liver cells plays a role in Nonalcoholic Fatty Liver Disease (NAFLD). In the liver, it is the type of fatty acid, not the quantity, that determines the extent of the lipotoxic effects. In hepatocytes, the ratio of monounsaturated fatty acids and saturated fatty acids leads to apoptosis and liver damage. There ...